The Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease (FLOW study; NCT03819153) is the first dedicated kidney outcome trial with a GLP-1 receptor agonist that was halted prematurely due to meeting prespecified criteria for efficacy, with detailed results anxiously expected in 2024. Here, GLP1R is linked to chronic kidney disease.